期刊文献+

伐地那非治疗尘肺合并肺动脉高压患者的疗效观察 被引量:2

Observation of efficacy of vardenafil in the treatment of pneumoconiosis patients complicated with pulmonary hypertension
下载PDF
导出
摘要 目的探讨伐地那非治疗尘肺合并肺动脉高压患者的疗效。方法 33例尘肺合并肺动脉高压患者随机分成治疗组(n=22)和对照组(n=11),治疗组给予伐地那非口服,每日1次,每次5mg,持续4周,若没有严重药物不良反应发生,增加到目标剂量每日2次,每次5mg,12周为一疗程;对照组口服相同剂量的安慰剂,对比两组患者治疗前后6分钟步行距离、肺动脉压、Borg呼吸困难评分、动脉血学氧饱和度。结果两组患者在年龄、病情严重程度(6分钟步行距离、肺动脉压、Borg呼吸困难评分、血氧饱和度)差异无统计学意义(P>0.05);在12周后,治疗组6分钟步行距离、肺动脉压、Borg呼吸困难评分、血氧饱和度明显改善,差异具有统计学意义(P<0.05),但对照组上述指标无明显改变(P>0.05),治疗组只有轻微短暂的不良反应。结论在尘肺合并肺动脉高压患者中,伐地那非疗效明确且耐受性良好。 Objective To evaluate the effect of vardenafil in the treatment of pneumoconiosis patients com-plicated with pulmonary arterial hypertension. Methods 33 pneumoconiosis patients complicated with pulmonary ar-terial hypertension were randomly divided into the treatment group ( n=22 ) and the control group ( n=11 ) . The treatment group was given vardenafil orally 5mg once everyday for 4 weeks, and it was sequentially increased to twice a day of 5mg if no adverse drug reactions occurred. The total course of treatment was 12 weeks. The control group was given the same dose of placebo. Before and after the treatment, 6-minute walking distance, pulmonary arterial pressure, Borg scale scores and SaO2 were measured. Results There was no significant difference in age and severi-ty of illness (6-min walk distance, pulmonary arterial pressure, Borg scale scores and SaO2)before the treatment. 12 weeks after the treatment, the parameters abov improved more obviously in the treatment group than in the control group (P〈0. 05). There were mild adverse reactions in the treatmen group. Conclusion Vardenafil is not only an effective drug but also has good tolerance in the treatment of pneumoconiosis patients complicated with pulmonary ar-terial hypertension.
出处 《临床肺科杂志》 2014年第12期2211-2213,共3页 Journal of Clinical Pulmonary Medicine
关键词 伐地那非 尘肺 肺动脉高压 vardenafil pneumoconiosis pulmonary arterial hypertension
  • 相关文献

参考文献11

  • 1Humbert M, Sithon O, Simonnean G. Treatment of pulmonary arte- rial hypertension[ J]. N Eagl J Med,2004,351 : 1425 - 1436.
  • 2Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction[J]. Am J Cardiol,2003,92(9A) :9 -18.
  • 3Jing ZC, Jiang X, Wu BX, et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study[J]. Heart,2009,95(18) :1531 -6.
  • 4Hoeper MM, Bogaard H J, Condliffe R,et al. Definitions and diag-nosis of pulmonary hypertension[ J]. J Am Coll Cardiol,2013,62 (25 Suppl) :D42 -50.
  • 5周学中,张维君.肺动脉高压治疗进展[J].中华胸心血管外科杂志,2010,26(5):356-358. 被引量:3
  • 6王毅,解卫平.肺动脉高压发病机制的研究进展[J].临床肺科杂志,2010,15(11):1621-1623. 被引量:26
  • 7Abman SH. Inhaled nitric oxide for the treatment of pulmonary ar- terial hypertension[ J]. Handb Exp Pharmaeol,2013,218:257 - 76.
  • 8Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2013,188 (6) : 639 - 46.
  • 9Jing ZC, Yu ZX, Shen JY,et al. Vardenafil in pulmonary arterial hypertension : a randomized, double-blind, placebo-controlled study[ J]. Am J Respir Crit Care Med,2011,183(12) :1723 -9.
  • 10Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmo- nary arterial hypertension: a randomized trial [ J ]. Ann Intern Med,2008,149 (8) :521 - 30.

二级参考文献21

  • 1Barst RJ,Langleben D,Badesch D,菅鑫妍.使用选择性内皮素A受体拮抗剂sitaxsentan治疗肺动脉高压[J].中国处方药,2006,5(8):29-29. 被引量:38
  • 2冯娟,王玉林.儿童肺动脉高压遗传学及细胞分子学研究进展[J].实用儿科临床杂志,2006,21(22):1580-1582. 被引量:3
  • 3Zaiman A,Fijalkowska L,Hassoun PM,et al.One hundred years of research in the pathogenesis of pulmonary hypertension[J].Am J Respir Cell Mol Biol,2005,33(5):425-431.
  • 4Simonneau G,Galie N,Rubin LJ,et al.Clinical classification of pulmonary hypertension[J].Am Coll Cardiol,2004,43:5s-12s.
  • 5Firth AL,Yuill KH,Smirnov SV.Mitochondria-dependent regulation of Kv currents in rat pulmonary artery smooth muscle cells[J].Am J Physiol Lung Cell Mol Physiol,2008,295 (1):L61-70.
  • 6Bonnet S,Rochefort G,Sutendra G,et al.The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted[J].Proc Natl Acad Sci U S A,2007,104(27):11418-11423.
  • 7De Frutos S,Duling L,Alo D,et al.NFATc3 is required for intermittent hypoxia-induced hypertension[J].Am J Physiol Heart Circ Physiol,2008,294(5):H2382-2390.
  • 8Zhao YD,Courtman DW,Deng Y,et al.Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelia-like progenitor cells:efficacy of combined cell and eNOS gene therapy in established disease[J].Circ Res,2005,96:442-450.
  • 9Asosingh K,Aldred MA,Vasanji A,et al.Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension[J].Am J Pathol,2008,172(3):615-627.
  • 10Chan SY,Loscalzo J.Pathogenicmechanisms of pulmonary arterial hypertension[J].J Mol Cell Cardiol,2008,44(1):14-30.

共引文献27

同被引文献17

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部